ConductScience.org, home

Paper41239747

Development of Peptide Glucosyltransferase Inhibitors With Comprehensive Coverage Across Clostridioides difficile Toxin B Sub-Types.

Catella CM and 10 others. Biotechnol Bioeng, 2026. Cited by 3 papers, by iCite.

Cite this record

ConductScience Library. Development of Peptide Glucosyltransferase Inhibitors With Comprehensive Coverage Across Clostridioides difficile Toxin B Sub-Types. Papers, record 41239747. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41239747

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Development of Peptide Glucosyltransferase Inhibitors With Comprehensive Coverage Across Clostridioides difficile Toxin B Sub-Types.
PubMed
Journal
Biotechnol Bioeng
PubMed
Year
2026
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
3
iCite
Revised in PubMed
2026-08-25
PubMed

Authors11

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Catella CMCarly M
2Sarma SSudeep
3Hinesley CMCaroline M
4Febo CECorey Ehttps://orcid.org/0000-0001-8872-5433
5Breau KAKeith A
6Durmusoglu DDeniz
7Purnell EEthan
8Magness STScott T
9Hall CKCarol K
10Menegatti SStefanohttps://orcid.org/0000-0001-5633-434X
11Crook NNathanhttps://orcid.org/0000-0001-6165-1972

Source PubMed

Download CSV of authors

Topics8

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Bacterial ToxinsMajor topic
Bacterial ProteinsMajor topic
Clostridioides difficileMajor topic
GlucosyltransferasesMajor topic
PeptidesMajor topic
Enzyme InhibitorsMajor topic
Humans
Anti-Bacterial Agents

Source PubMed

Download CSV of topics

Grants3

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
R56 AI177728NIAID NIH HHSUnited StatesR56AI177728PubMedNIH RePORTER
T32 GM133366NIGMS NIH HHSUnited StatesT32GM133366PubMedNIH RePORTER
National Institutes of Health; North Carolina Biotechnology Center; Novo Nordisk Fonden; National Science Foundation.PubMedPubMed

Download CSV of grants

References78

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
129617739Results From a Randomized, Placebo-Controlled Clinical Trial of a RBX2660-A Microbiota-Based Drug for the Prevention of Recurrent Clostridium difficile Infection.Clin Infect Dis2018https://conductscience.org/library/papers/29617739PubMed
224311789Structural basis for antibody recognition in the receptor-binding domains of toxins A and B from Clostridium difficile.J Biol Chem2014https://conductscience.org/library/papers/24311789PubMed
319394704Recurrent Clostridium difficile infection: a review of risk factors, treatments, and outcomes.J Infect2009https://conductscience.org/library/papers/19394704PubMed
431756084Discovery and Evaluation of Peptide Ligands for Selective Adsorption and Release of Cas9 Nuclease on Solid Substrates.Bioconjug Chem2019https://conductscience.org/library/papers/31756084PubMed
521231971Structural determinants for membrane insertion, pore formation and translocation of Clostridium difficile toxin B.Mol Microbiol2011https://conductscience.org/library/papers/21231971PubMed
626862400Recent advances in the understanding of antibiotic resistance in Clostridium difficile infection.Ther Adv Infect Dis2016https://conductscience.org/library/papers/26862400PubMed
727680706Frizzled proteins are colonic epithelial receptors for C. difficile toxin B.Nature2016https://conductscience.org/library/papers/27680706PubMed
832903430Human α-Defensin-5 Efficiently Neutralizes Clostridioides difficile Toxins TcdA, TcdB, and CDT.Front Pharmacol2020https://conductscience.org/library/papers/32903430PubMed
99312171Toxins A and B from Clostridium difficile differ with respect to enzymatic potencies, cellular substrate specificities, and surface binding to cultured cells.J Clin Invest1997https://conductscience.org/library/papers/9312171PubMed
1026037121Defining the Roles of TcdA and TcdB in Localized Gastrointestinal Disease, Systemic Organ Damage, and the Host Response during Clostridium difficile Infections.mBio2015https://conductscience.org/library/papers/26037121PubMed
1135058787Inhibition of Clostridioides difficile Toxins TcdA and TcdB by Ambroxol.Front Pharmacol2021https://conductscience.org/library/papers/35058787PubMed
1234882774Protease-stable DARPins as promising oral therapeutics.Protein Eng Des Sel2021https://conductscience.org/library/papers/34882774PubMed
1329741092Advancing Peptide-Based Biorecognition Elements for Biosensors Using in-Silico Evolution.ACS Sens2018https://conductscience.org/library/papers/29741092PubMed
1416344467Crystal structure of receptor-binding C-terminal repeats from Clostridium difficile toxin A.Proc Natl Acad Sci U S A2005https://conductscience.org/library/papers/16344467PubMed
1517901056Clostridium difficile glucosyltransferase toxin B-essential amino acids for substrate binding.J Biol Chem2007https://conductscience.org/library/papers/17901056PubMed
1629180448A neutralizing antibody that blocks delivery of the enzymatic cargo of Clostridium difficile toxin TcdB into host cells.J Biol Chem2018https://conductscience.org/library/papers/29180448PubMed
1720863124Peptide inhibitors targeting Clostridium difficile toxins A and B.ACS Chem Biol2010https://conductscience.org/library/papers/20863124PubMed
1832255488SER-109, an Investigational Microbiome Drug to Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial.Clin Infect Dis2021https://conductscience.org/library/papers/32255488PubMed
1938717124Fecal microbiota transplantation: current challenges and future landscapes.Clin Microbiol Rev2024https://conductscience.org/library/papers/38717124PubMed
2025451052Broad coverage of genetically diverse strains of Clostridium difficile by actoxumab and bezlotoxumab predicted by in vitro neutralization and epitope modeling.Antimicrob Agents Chemother2015https://conductscience.org/library/papers/25451052PubMed

See all 78 referencesDownload CSV of references

Cited by3

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.

PMIDTitleJournalYearIn PapersSource
42291326A single amino acid substitution determines susceptibility of Clostridioides difficile toxin B variants to monoclonal antibody neutralization.Front Cell Infect Microbiol2026https://conductscience.org/library/papers/42291326PubMed
41991729Novel endogenous protein-based strategies to inhibit clinically relevant bacterial AB-type toxins including pertussis toxin.Arch Toxicol2026https://conductscience.org/library/papers/41991729PubMed
41239747Development of Peptide Glucosyltransferase Inhibitors With Comprehensive Coverage Across Clostridioides difficile Toxin B Sub-Types.Biotechnol Bioeng2026https://conductscience.org/library/papers/41239747PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41239747

GET https://conductscience.org/api/papers/v1/41239747/references?page=2